Exagen (NASDAQ:XGN) Stock: Insider Jorey Chernett Acquires 7,085 Shares

Exagen Inc. (NASDAQ:XGN) major shareholder Jorey Chernett acquired 7,085 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The stock was purchased at an average cost of $5.26 per share, for a total transaction of $37,267.10. Following the acquisition, the insider owned 2,625,625 shares in the company, valued at approximately $13,810,787.50. This trade represents a 0.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The shares were sold at an average price of $6.14, for a total transaction of $69,167.10.
• On Monday, November 9th, Jorey Chernett bought 8,500 shares of Exagen stock. The shares were purchased at an average cost of $6.35 per share, with a total value of $53,975.00.
• On Monday, October 19th, Jorey Chernett bought 14,000 shares of Exagen stock. The shares were purchased at an average cost of $7.46 per share, with a total value of $104,440.00.

Exagen Price Performance

NASDAQ XGN opened at $5.03 on Thursday. Exagen Inc. has a 52 week low of $2.59 and a 52 week high of $9.73. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 1.96. The stock has a market cap of $121.85 million, a price-to-earnings ratio of -6.71 and a beta of 2.25. The company has a 50-day moving average price of $7.84 and a two-hundred day moving average price of $5.13.

Exagen (NASDAQ:XGN) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The business had revenue of $18.42 million for the quarter, compared to the consensus estimate of $18.34 million. Exagen had a negative net margin of 25.14% and a negative return on equity of 123.63%. Analysts forecast that Exagen Inc. will post -0.69 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. FourWorld Capital Management LLC grew its holdings in Exagen by 61.2% during the first quarter. FourWorld Capital Management LLC now owns 439,950 shares of the company’s stock worth $1,320,000 after acquiring an additional 166,950 shares during the period. Flputnam Investment Management Co. bought a new stake in Exagen in the second quarter worth about $1,343,000. Sei Investments Co. lifted its holdings in Exagen by 107.0% in the 1st quarter. Sei Investments Co. now owns 244,240 shares of the company’s stock valued at $733,000 after acquiring an additional 126,235 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Exagen in the 2nd quarter valued at about $998,000. Finally, Renaissance Technologies LLC lifted its holdings in Exagen by 47.3% in the 1st quarter. Renaissance Technologies LLC now owns 203,272 shares of the company’s stock valued at $610,000 after acquiring an additional 65,272 shares during the last quarter. Institutional investors own 75.25% of the company’s stock.

Top Exagen Stories

Here are a few of the latest stories about XGN:

• Positive Sentiment: Q3 revenue increased 7% year over year to $18.4 million, slightly ahead of estimates. For the first nine months, revenue rose 11%, net loss narrowed 12%, and adjusted EBITDA loss improved by more than 30%. Exagen Q3 results
• Positive Sentiment: Exagen reiterated its 2026 revenue outlook of $72 million to $75 million and remains on track to launch its myositis offering in early 2027. A major shareholder’s recent purchases also exceeded his reported sale in the cited transactions, a modest supportive signal. Insider transaction report
• Neutral Sentiment: BTIG reaffirmed its Buy rating and $9 target. Canaccord also kept a Buy rating but cut its target from $11 to $9, tempering the positive analyst outlook. Canaccord analyst rating

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. TD Cowen raised their target price on Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Exagen in a research report on Wednesday, November 4th. Canaccord Genuity Group decreased their price target on Exagen from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday. B. Riley Financial started coverage on Exagen in a research note on Friday, September 11th. They issued a “buy” rating and a $12.00 price target for the company. Finally, BTIG Research reissued a “buy” rating and set a $9.00 price target on shares of Exagen in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.88.

About Exagen

Exagen Inc. is a commercial-stage diagnostic company focused on improving the diagnosis and management of autoimmune and rheumatic diseases. The company develops and commercializes blood tests that help physicians identify autoimmune disease, distinguish among related conditions and monitor disease activity over time. Its principal product family is AVISE, which includes the AVISE CTD and AVISE Lupus tests, as well as monitoring and specialty tests used in the evaluation of systemic lupus erythematosus and other connective-tissue diseases.